ACRO Biomedical Co., Ltd. (TPEX:6748)
Taiwan · Delayed Price · Currency is TWD 79.50
+4.20 (5.58%)
Sep 5, 2025, 1:47 PM CST
ACRO Biomedical Revenue
In the year 2024, ACRO Biomedical had annual revenue of 44.23M TWD, down -13.38%. ACRO Biomedical had revenue of 23.19M in the half year ending December 31, 2024, with 89.69% growth.
Revenue
44.23M
Revenue Growth
-13.38%
P/S Ratio
111.28
Revenue / Employee
n/a
Employees
n/a
Market Cap
4.92B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44.23M | -6.83M | -13.38% |
| Dec 31, 2023 | 51.06M | 23.43M | 84.79% |
| Dec 31, 2022 | 27.63M | 5.81M | 26.59% |
| Dec 31, 2021 | 21.83M | 3.80M | 21.04% |
| Dec 31, 2020 | 18.03M | 10.71M | 146.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Caliway Biopharmaceuticals | 44.83M |
| PharmaEssentia | 12.63B |
| Bora Pharmaceuticals Co., LTD. | 21.32B |
| Lotus Pharmaceutical | 19.12B |
| Lumosa Therapeutics | 37.25M |
| Oneness Biotech | 112.57M |
| Polaris Group | 64.02M |
| Center Laboratories | 1.60B |